European Panel OKs Approval of Triple Combination Therapies for Multiple Myeloma Patients
The European Medicines Agency‘s (EMA) Committee for Medicinal…
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreWhile myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreThe European Medicines Agency‘s (EMA) Committee for Medicinal…
The U.S. Food and Drug Administration is delaying its…
An application has been submitted seeking U.S. approval of…
The U.S. Food and Drug Administration (FDA) has placed…
The expansion part of a Phase 1/2 clinical trial…
A triple combination of Darzalex (daratumumab), Velcade…